Oxford Biomedica Obtains Further Fundamental Patent For Lentiviral Gene Therapy Technology
Oxford BioMedica plc announced today that it has received allowance from the US Patent Office for a further patent covering its proprietary LentiVector technology. This additional patent compliments the US patent 6,312,682 issued in November 2001 and both include broad composition of matter claims and methods of production claims for lentiviral vector gene delivery systems of both human and non-human origin. This patent adds further strength to Oxford BioMedica's existing patents that cover derivatives of lentiviral vector systems that, unlike many versions of lentiviral vectors, have real clinical utility because of their safety. The Oxford BioMedica team was the first to construct lentivi